- Report
- April 2025
- 145 Pages
Global
From €2815EUR$3,160USD£2,434GBP
€3518EUR$3,950USD£3,043GBP
- Report
- May 2025
- 110 Pages
Global
From €4231EUR$4,750USD£3,659GBP
- Report
- May 2025
- 120 Pages
Global
From €4231EUR$4,750USD£3,659GBP
- Report
- December 2024
- 200 Pages
Global
From €3340EUR$3,750USD£2,889GBP
- Report
- December 2024
- 196 Pages
Global
From €2227EUR$2,500USD£1,926GBP
- Report
- June 2025
- 400 Pages
Global
From €4408EUR$4,949USD£3,813GBP
- Report
- June 2025
- 229 Pages
Global
From €2227EUR$2,500USD£1,926GBP
- Report
- March 2025
- 371 Pages
Global
From €3963EUR$4,450USD£3,428GBP
- Report
- January 2025
- 146 Pages
Global
From €2815EUR$3,160USD£2,434GBP
€3518EUR$3,950USD£3,043GBP
- Report
- August 2024
- 140 Pages
Global
From €2815EUR$3,160USD£2,434GBP
€3518EUR$3,950USD£3,043GBP
- Report
- June 2025
- 127 Pages
Global
From €2627EUR$2,950USD£2,273GBP
- Report
- April 2025
- 30 Pages
Global
From €2627EUR$2,950USD£2,273GBP
- Report
- January 2025
- 127 Pages
Global
From €2627EUR$2,950USD£2,273GBP
- Report
- July 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- June 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- June 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- May 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- April 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- February 2025
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP
- Report
- November 2024
- 150 Pages
Global
From €3429EUR$3,850USD£2,966GBP
€4320EUR$4,850USD£3,736GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more